Summary
A phase I trial of 2-β-D-ribofuranosylthiazole-4-carboxamide (NCS 286193, tiazofurin) was conducted using a 5-day i.v. bolus schedule, every 21 days. Thirty one patients with advanced cancer were entered on the trial. A total of 106 cycles were administered with doses ranging from 550 to 2750 mg/m2. Concomitant administration of Allopurinol was necessary to prevent hyperuricemia. Tiazofurin was difficult to evaluate and many side effects were variable and sporadic. The dose limiting toxicities were nonhematologic consisting particularly of myalgias, headaches and general malaise. Other toxicities included nausea, vomiting, stomatitis, lethargy, sleeping difficulty, sinus bradycardia, skin rash, desquamation of the palms and soles, photophobias and burning of the eyes.
Hematologic toxicity was mild and not dose related though it led to a neutropenic septic death in one patient at 2750 mg/m2. Anemia was documented in 60% of cycles. Biochemical abnormalities consisted of mild hyperglycemia, hyperuricemia and elevated skeletal creatinine phosphokinase levels which did not correlate with the incidence or degree of myalgias. Though some patients were able to tolerate higher doses, the recommended dose for phase 2 study is 1650 mg/m2. Further studies will be required to achieve a better understanding of this interesting drug.
Similar content being viewed by others
References
Witkowski JT, Robins RK, Sidwell RW, Simon LN: Design synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 15: 1150–1154, 1972
Clinical Brochure. Tiazofurin. Bethesda, MD: National Cancer Institute, March 1983
O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon J, Davignon JP, Davis RD: Tiazofurin: a new antitumor agent. Invest New Drugs 2: 79–84, 1984
Robins RK, Strivastava PC, Narayanan VL, Plowman J, Paul KD: 2-β-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J Med Chem 25: 107–108, 1982
Earle MF, Glazer RI: Activity and metabolism of 2-β-D-ribofuranosylthiazole-4-carboxamide in human lymphoid tumor cells in culture. Cancer Res 43: 133–137, 1983
Melink TJ, Von Hoff DD, Clark G: Antitumor activity of Tiazofurin in a human tumor cloning system. (Abstr) Proc Am Assoc Cancer Res 25: 375, 1984
Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE, Johns DG: The conversion of 2-β-D-ribo-furanosylthiazole-4-carboxamide to an analogue of NAD with IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 31: 2133–2136, 1982
Jayaram HN, Dion RL, Glazer RI, Johns DG, Robins RK, Srivastava PC, Cooney DA: Initial studies on the mechanism of action of a new oncolytic thiazol nucleoside, 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol 31: 2371–2380, 1982
Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA: Studies on the mechanism of action of 2-β-D-ribofuranosyrthiazole-4-carboxamide (NSC 286193). II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 31: 3839–3845, 1982
Lui MS, Faderan MA, Liepnieks JJ, Natsumada Y, Olah E, Jayaram HN, Weber G: Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide). J Biol Chem 259: 5078–5082, 1984
Green RM, Stewart DJ, Maroun JA: Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Invest New Drugs 4: 387–394, 1986
Eagan RT, Fleming TR, Schoonover V: Evaluation of response criteria in advanced lung cancer. Cancer 44: 1125–1128, 1979
Trump DL, Tutsch KD, Koeller JM, Tormey DC: Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five day infusion. Cancer Res 45: 2853–2858, 1985
Batist G, Klecker Jr RW, Jayaram HN, Jenkins JF, Grygiel J, Ihde DC, Eddy JL, Fine RL, Kerr IG, Collins JM: Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286192) administered by continuous infusion. Invest New Drugs 3: 349–355, 1985
Raghavan D, Bishop J, Sampson D, Grygiel J, Woods R, Coates A, Fox R: Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5 day continuous infusion. Cancer Chemother Pharmacol 16: 160–164, 1986
Balis FM, Lange BJ, Packer RJ, Holcenberg JS, Ettinger LJ, Sallan SE, Heideman RL, Zimm S, Smithson WA, Cogliano-Shutta NA, Reaman GH, Poplack DG: Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res 45: 5169–5172, 1985
Melink TJ, Von Hoff DD, Kuhn JG, Hersh MR, Sternson LA, Patton TF, Siegler R, Boldt DH, Clark GM: Phase I evaluation and pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 45: 2859–2865, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maroun, J.A., Stewart, D.J. Phase I study of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Invest New Drugs 8 (Suppl 1), S33–S39 (1990). https://doi.org/10.1007/BF00171982
Issue Date:
DOI: https://doi.org/10.1007/BF00171982